Apotheca Research
The science behind what works. Peptides, supplements, and longevity research reviewed.
Semaglutide for PCOS: Weight Loss, Insulin Resistance, and Fertility
Semaglutide for PCOS: Weight Loss, Insulin Resistance, and Fertility Semaglutide for PCOS: Weight Loss, Insulin Resistance, and Fertility Semaglutide for PCOS refers...
AOD-9604: The Fat Loss Fragment Peptide
AOD-9604: The Fat Loss Fragment Peptide | Research AOD-9604: The Fat Loss Fragment Peptide AOD-9604 is a synthetic peptide fragment derived from...
Compounded Semaglutide in 2026: What Changed and What's Still Available
Compounded Semaglutide in 2026: What Changed and What's Still Available Compounded Semaglutide in 2026: What Changed and What's Still Available Compounded semaglutide...
Peptides for Weight Loss: A Research-Based Guide to What Actually Works
Peptides for Weight Loss: A Research-Based Guide to What Actually Works Peptides for Weight Loss: A Research-Based Guide to What Actually Works...
Berberine: The Blood Sugar Supplement That Rivals Metformin in Studies
Berberine: The Blood Sugar Supplement That Rivals Metformin in Studies Berberine: The Blood Sugar Supplement That Rivals Metformin in Studies Berberine is...
Berberine: The 'Nature's Ozempic' Claim and What the Evidence Actually Shows
Berberine: The 'Nature's Ozempic' Claim and What the Evidence Actually Shows Berberine: The 'Nature's Ozempic' Claim and What the Evidence Actually Shows...
GLP-1 Peptides and Alcohol Use Disorder: The Science Behind Lilly's Brenipatide
In November 2025, Eli Lilly quietly registered two Phase 3 clinical trials that could reshape how the world thinks about peptide therapeutics....
Orforglipron Beat Oral Semaglutide. The Data Is In.
The first head-to-head trial between two oral GLP-1 receptor agonists has concluded. Orforglipron, Eli Lilly's small-molecule GLP-1 agonist, outperformed oral semaglutide across...
Tirzepatide: Dual Agonism and the Future of GIP/GLP-1 Research
The first dual GIP/GLP-1 receptor agonist to reach Phase 3 trials almost didn't happen. When Frias et al. published early tirzepatide data...
Semaglutide: The GLP-1 Agonist That Changed Metabolic Research
Semaglutide arrived in laboratories with a structural modification so subtle that most peptide researchers initially overlooked its implications. A single C-18 fatty...
Semaglutide vs Tirzepatide: A Research Comparison
The pharmaceutical industry has produced two structurally similar yet mechanistically distinct peptides that have redefined metabolic research protocols. Semaglutide and tirzepatide both...
Semaglutide Patent Expiration and the Evolving Compounding field in 2026
The semaglutide market is undergoing seismic shifts in 2026. With India's patent expiration in March 2026 enabling generic production and ongoing regulatory...
Peptides for Weight Loss Research: Mechanisms, Evidence, and Regulatory Status
The pharmaceutical industry has pursued weight loss compounds for decades. Most failed. They worked temporarily, produced intolerable side effects, or both. Then...
AOD-9604: The Growth Hormone Fragment for Metabolic Research
AOD-9604 is 16 amino acids that don't make you taller. This matters because its parent molecule, human growth hormone (hGH), definitely does....
5-Amino-1MQ: NAD+ Salvage and Metabolic Research
5-Amino-1MQ appears frequently in peptide research supplier catalogs despite not being a peptide. This small molecule inhibitor of nicotinamide N-methyltransferase found its...